Starting June 1, Blue Cross will no longer cover Sajazir injection

Starting June 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network will no longer cover Sajazir™ injection as a pharmacy benefit. Instead, we’ll cover generic icatibant acetate subcutaneous injection. Sajazir is a medication commonly used to treat acute attacks of hereditary angioedema. 

Both Sajazir and icatibant acetate subcutaneous injection are generic icatibant acetate products for brand name Firazyr^® and are FDA-approved. However, Sajazir is more expensive than other available generic products. It also requires limited distribution through LeMed Specialty Pharmacy^©, a nonpreferred specialty pharmacy, whereas the other generic products are available through specialty pharmacies. Our preferred specialty pharmacy is AllianceRx Walgreens Pharmacy.

If your patient requires treatment with Sajazir rather than another generic product after June 1, a medical necessity review will be required.

We’ll notify affected members of these changes and encourage them to talk with you to address any concerns and get a new prescription, if needed.

If you have questions, call the Pharmacy Services Clinical Help Desk at 1-800-437-3803.